RLAY Stock Recent News

Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.71 per share a year ago.

Relay Therapeutics' early clinical data for cancer drug RLY-2608 sparked investor concerns due to lack of robust evidence of efficacy, leading to a 40% stock decline. Despite investor skepticism, analysts believe the sell-off was an overreaction, highlighting the drug's potential and the validation of Relay's Dynamo platform. Relay Therapeutics also has promising lead assets RLY-4008 and GDC-1971, and despite short-term investor sentiment, the company's long-term potential remains strong.

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in two upcoming fireside chats:

Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.61 per share a year ago.

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2023 financial results and corporate highlights after the close of market on Thursday, May 4, 2023. The company will not be conducting a teleconference in conjunction with its financial results press release.

CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two upcoming fireside chats:

Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 94.8% in Relay Therapeutics, Inc. (RLAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Relay Therapeutics to host conference call following AACR presentation Relay Therapeutics to host conference call following AACR presentation

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month, at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET and the Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 4:05 p.m. ET.